{"id":207922,"name":"ARDELYX, INC.","slug":"ardelyx-inc","state":"MA","country":"United States of America","description":"","totalSpending":9450000,"filings":25,"yearlySpending":[{"year":2020,"income":170000},{"year":2021,"income":1170000},{"year":2022,"income":520000},{"year":2023,"income":1510000},{"year":2024,"income":2450000},{"year":2025,"income":3630000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["ARDELYX, INC."],"lobbyists":["TRICIA BROOKS","PAUL PEREIRA","MATTHEW LASH","KENNETH SPRAGUE","REBECCA WALDROP","ZACHARY KRIBS","KENNY HODGE","BEAU SCHUYLER","YUL EDWARDS","VIN ROBERTI","STEVE IRIZARRY","LYNDON BOOZER","JEFF CARROL","GERRY HARRINGTON","JOHN MCMANUS","THERESA JOLIVETTE"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Office of Management & Budget (OMB)"],"sampleDescriptions":["Congressional education and advocacy regarding patient access to innovative cardiorenal biopharmaceuticals.","Congressional education and advocacy regarding patient access to innovative cardiorenal biopharmaceuticals.","- Issues related to Medicare ESRD benefit and chronic kidney disease management.","-  Issues related to medication affordability and access.\n- Issues related to Prescription Drug User Fee Act amendments.","Issues related to medication affordability and access."]}